RxDoctor Payments Data

Owais Zaidi, MD

Critical Care Medicine · Pomona, CANPI 1588825095

Payments from drug & device makers

$2,163in general payments, 2019–2025

Across 102 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$665
  • Regeneron Healthcare Solutions, Inc.$607
  • Abiomed$130
  • Paratek Pharmaceuticals, Inc.$125
  • Boehringer Ingelheim$121
  • Portola Pharmaceuticals, LLC$109
  • plus $406 from 10 others

What the payments were for

  • Food & beverage$2,09397%
  • Education$703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,163 in reported general payments places this provider in the 70th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$469,001
Medicare patients
915
Services billed
4,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate23$299,144
Trelegy ElliptaFluticasone/Umeclidin/Vilanter198$130,332
SymbicortBudesonide/Formoterol Fumarate32$9,768
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,546
Breo ElliptaFluticasone/Vilanterol16$5,977
Spiriva RespimatTiotropium Bromide11$5,607
Wixela InhubFluticasone Propion/Salmeterol33$4,244
BreynaBudesonide/Formoterol Fumarate15$3,437
Albuterol Sulfate HfaAlbuterol Sulfate99$2,730
Ventolin HfaAlbuterol Sulfate16$842
Roflumilast12$633
Methylprednisolone57$374
Montelukast Sodium43$215
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$168
Azithromycin34$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$121$304,75134 claims
GSKTrelegy Ellipta, Breo Ellipta$665$136,309214 claims
AstraZenecaSymbicort, Breztri Aerosphere$37$17,31445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Pomona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →